What Is Burning Mouth Syndrome?
Burning mouth syndrome (BMS) is a chronic condition where your mouth, tongue, lips, or palate burn. However, your dentist doesn't see anything wrong when they look. The burning happens more than 4 hours daily for at least 3 months. Your mouth looks normal (no ulcers, sores, or discoloration visible). You can't find an obvious cause like a yeast infection, allergy, or other treatable problem.
The burning sensations are usually bilateral and symmetric (on both sides equally), not on just one side. You'd describe it as burning, tingling, or numbness. Not sharp, stabbing pain.
Severity ranges from mild (you're aware of it but it doesn't interfere much) to severe (it affects eating, drinking, and quality of life). Pain typically worsens through the day, worst in afternoon/evening. But you wake up without symptoms, which is unusual. Stress and fatigue make it worse.
There are three types. Primary BMS (60-70% of cases) has no identifiable cause. Secondary BMS (30-40% of cases) happens alongside something else you can identify and potentially treat.
Like yeast infection, lichen planus, or medicine side effects. Tertiary BMS is pain that persists even after treating the underlying cause. This suggests chronic changes in how your nervous system processes pain.
Who Gets Burning Mouth Syndrome?
BMS affects 0.7-4.6% of people overall. Postmenopausal women get it much more (5-15% of that group). Peak ages are 40-70, with a 3:1 female-to-male ratio. It's 2-3 times more common in people over 60 than younger people.
Risk factors include menopause (3-4 times higher risk compared to premenopausal women), depression and anxiety (common in BMS patients), dry mouth (40-50% of BMS patients), and wearing dentures (15-20% of BMS patients). Certain medicines increase risk: anticonvulsants, blood pressure medicines, and antihistamines. Denture material allergies are rare (under 5%) but possible.
Vitamin B12, folate, or iron deficiency occurs in 10-15% of BMS patients. Supplements sometimes helps these patients. Hormone changes matter.
Estrogen deficiency in menopause is a major risk factor. Hormone replacement therapy helps some women. Thyroid disorders (especially hypothyroidism) show increased BMS risk.
Why the Burning Happens
The exact cause remains unclear, but several processes are involved. Trigeminal nerve problem (the major nerve supplying your mouth) appears significant. Studies show abnormal nerve responses in many BMS patients. Central sensitization (the brain amplifying pain signals) seems important. Brain imaging shows altered activity in pain-processing areas.
Salivary problem contributes. Reduced saliva predisposes to yeast infections (which burn). It loses protective proteins that shield mouth tissue.
Altered saliva composition might affect nerve function. Neurotransmitter imbalances (especially low serotonin) reduce pain inhibition. That's why antidepressants sometimes help. Abnormal taste perception (30-40% of BMS patients) suggests taste nerve involvement.
Ruling Out Other Problems
Your dentist must exclude other causes. Oral candidiasis (yeast—causes visible white patches) responds to antifungal rinses. Oral lichen planus (autoimmune condition—shows visible erosions or white patches) responds to topical steroids.
Xerostomia (dry mouth—low saliva flow) has measurable reduced saliva production. Trigeminal neuralgia (sharp, shooting pain) differs from BMS burning and responds to anticonvulsants. TMJ problem (jaw joint pain) differs from BMS.
Allergies to toothpaste, denture materials, or foods cause localized burning. This improves when the allergen is removed. Herpes causes painful blisters that evolve to erosions.
Your dentist might order blood tests to exclude deficiencies. Panoramic X-rays exclude dental pathology (infections, impacted teeth) contributing to pain. Further imaging is typically unnecessary.
Neurophysiologic Mechanisms and Pathophysiology
Current evidence suggests BMS represents neuropathic pain condition involving trigeminal and taste nerve pathology. Precise processes remain incompletely understood. Several neurophysiologic abnormalities have been documented in BMS patients.
Abnormal nerve tests show reduced trigeminal nerve responses in BMS patients compared to controls. This suggests peripheral trigeminal nerve problem. However, not all BMS patients show objective neurophysiologic abnormalities. This suggests heterogeneous etiology.
Central sensitization processes appear significant in BMS pathophysiology. Chronic pain generates changes in the central nervous system increasing pain signal amplification. Brain imaging studies show altered brain activity patterns in regions processing pain in BMS patients compared to controls.
Sensory testing shows altered pain thresholds in BMS patients. Reduced pain thresholds to various stimuli (mechanical pressure, temperature) suggest heightened nociceptive soreness. Pain response to normally non-noxious tactile stimulation occurs in 30-40% of BMS patients.
Salivary problem may contribute to BMS through multiple processes. Reduced salivary flow predisposes to oral candidiasis (fungal infection producing oral burning and pain). Loss of salivary protective proteins reduces mucosal barrier integrity. Altered salivary ionic composition may affect sensory nerve function.
Serotonin and norepinephrine dysregulation appears significant. BMS patients show lower serotonin levels compared to controls. Reduced serotonergic neurotransmission impairs pain inhibitory pathways. SSRI efficacy in some patients supports serotonergic involvement.
Abnormal taste perception (dysgeusia) occurs in 30-40% of BMS patients. This suggests taste nerve involvement. Altered taste may represent primary nerve pathology or secondary consequence of chronic pain-related central changes.
Differential Diagnosis and Exclusionary Evaluation
Differential diagnosis of burning mouth sensation is critical. Many conditions produce similar symptoms. Oral candidiasis (fungal infection) produces burning sensation localized to affected areas with visible white plaques. Oral rinses with antifungal medicine produce symptom improvement if candidiasis is responsible.
Oral lichen planus produces burning pain with visible erosions or white patches on oral mucosa. Topical corticosteroids produce symptom improvement confirming inflammatory etiology.
Xerostomia (dry mouth) produces burning sensation secondary to reduced salivary protection and mucosal drying. Salivary flow measurement distinguishes xerostomia. Addressing underlying xerostomia through salivary stimulants or substitutes improves symptoms.
Trigeminal neuralgia produces sharp, shooting pain distinguishable from BMS burning sensation. Neuralgia shows unilateral distribution, sudden onset, and response to anticonvulsant medicine. Nerve compression from dental prosthetics produces localized pain responding to device adjustment or removal.
Temporomandibular joint problem produces jaw pain. Joint pathology assessment distinguishes through clinical exam or symptom response to TMJ-specific treatment.
Allergic reactions to oral hygiene products, denture materials, or food additives produce burning localized to exposed areas. Elimination of suspected causative agent and symptom resolution confirms allergic etiology.
Herpetic infections produce burning pain with visible blisters evolving to erosions. Antiviral medicine response distinguishes from BMS.
Laboratory assessment may include complete blood count, vitamin B12 level assessment, folate level assessment, thyroid function tests, and glucose testing. However, routine laboratory screening is not universally indicated unless clinical suspicion exists for specific deficiencies.
Imaging including panoramic X-rays excludes dental pathology (infections, impactions) that might contribute to pain. Additional imaging is not routinely indicated for BMS diagnosis unless clinical findings suggest other option pathology.
Treatment Options
Cognitive-behavioral therapy (CBT) reduces burning by 40-50% through changing pain cognitions, reducing anxiety, and building coping strategies. Psychological support is crucial. Many BMS patients worry they have cancer. Reassurance that BMS isn't cancer or systemic disease reduces anxiety much.
Xerostomia management (if you have dry mouth) helps. Use sugarless candies or xylitol gum to stimulate saliva. Saliva substitutes (artificial saliva products) provide lubrication. Prescription sialagogues (pilocarpine) chemically stimulate remaining salivary glands.
Dietary change helps 20-30% of patients. Eliminate acidic beverages, spicy foods, and very hot foods that irritate tissues. Try this for 4-6 weeks to see if it helps. Topical capsaicin (0.025% cream, 4-6 times daily) produces 40-50% symptom reduction through desensitization over several weeks.
But it burns initially. Topical anesthetics (benzocaine, lidocaine) provide temporary relief. Use cautiously to avoid numbness. Short-term use (a few minutes before meals) is safe.
Tricyclic antidepressants work best. Amitriptyline (10-50mg nightly) reduces pain 60-70%. Response develops gradually over 4-6 weeks. SSRIs (paroxetine, sertraline, fluoxetine at 20-40mg daily) reduce pain 30-50%.
They work slower (6-8 weeks). Gabapentin (900-3,600mg daily in divided doses, starting low and increasing gradually) helps 50-60% of patients. Benzodiazepines (clonazepam 0.5-2mg daily) provide temporary relief during flares. They aren't for long-term use (tolerance develops in 2-4 weeks).
Alpha-lipoic acid (600mg daily) has preliminary evidence for 40-50% improvement in some trials. Hormone replacement therapy helps postmenopausal women in some studies (50% improvement). However, weighing systemic risks is important. Specialist referral (orofacial pain specialist) is appropriate if standard management fails after 8-12 weeks.
Long-Term Outlook
About 30-50% of BMS patients experience natural remission within 6-12 years without treatment. That's encouraging but waiting is hard given the pain burden. 50-60% achieve significant symptom improvement (50%+ pain reduction) with appropriate treatment. 30-40% achieve complete symptom resolution within 12-18 months. Most patients require sustained medicine indefinitely. Stopping medicines usually brings symptoms back within weeks to months.
Treatment-resistant BMS (20-30% of patients not responding to standard approaches) might need multiple medicines, optimization of existing ones, or factor of experimental therapies. Support groups and educational resources reduce psychological burden and provide coping strategies from others with BMS.
Systemic Pharmacologic Therapy
Tricyclic antidepressants represent first-line systemic medicine. Amitriptyline is most commonly used. Dosing typically starts at 10mg nightly. It increases to 25-50mg nightly as tolerated. 60-70% of patients show moderate to significant improvement. Response develops gradually over 4-6 weeks.
Selective serotonin reuptake inhibitors (SSRIs) show variable efficacy. Paroxetine, sertraline, and fluoxetine (20-40mg daily) produce symptomatic improvement in 30-50% of patients. SSRIs typically show slower onset compared to tricyclics (6-8 weeks to maximum benefit).
Gabapentin shows efficacy in BMS. Dosing ranges from 900-3,600mg daily in divided doses. Typical dosing starts at 300mg nightly. It increases by 300mg increments every 3-4 days to minimize side effects. 50-60% of patients show significant improvement. Maximum benefit develops over 4-8 weeks.
Benzodiazepines (clonazepam 0.5-2mg daily) provide short-term symptom relief. They are not recommended for long-term use due to tolerance development and dependence potential. Brief use during acute symptom exacerbations may be appropriate with careful monitoring.
Alpha-lipoic acid (600mg daily) shows preliminary evidence for BMS symptom reduction. Efficacy is shown in 40-50% of patients in some trials. 6-12 week treatment trials assess individual responsiveness.
Hormone replacement therapy (HRT) benefits postmenopausal women with BMS in some studies. Symptom improvement occurs in about 50% of treated patients. However, HRT carries systemic risks. Benefits and risks must be carefully weighed with patient and her primary care physician.
Specialist Referral and Advanced Interventions
Orofacial pain specialists possess advanced training in BMS diagnosis and management. Referral is appropriate when primary care management is unsuccessful after 8-12 weeks of treatment. Or when diagnostic uncertainty persists. Or when complex medicine management is required.
Topical compounded medicines (combination preparations) prepared by compounding pharmacies provide mix therapy targeting multiple pain processes. These preparations lack robust clinical evidence. They may be considered for patients with inadequate response to standard treatments.
Oral mucosa biopsy is not routinely indicated for uncomplicated BMS. But it should be considered if clinical appearance suggests underlying pathology (erosions, white patches, ulcerations) despite clinical categorization as BMS.
Botulinum toxin injection to salivary glands increases salivary flow. Preliminary reports suggest BMS symptom reduction in some patients through improved salivary protection. However, evidence remains limited and this approach is considered experimental.
Low-level laser therapy shows preliminary promise for BMS. Evidence quality remains inconsistent. Trials typically employ laser wavelengths in 650-1,000nm range with varying treatment protocols.
Prognosis and Long-Term Management
Prognosis for BMS is variable. About 30-50% of patients experience natural remission within 6-12 years even without treatment. However, waiting for spontaneous remission is not recommended given the substantial pain burden and psychological impact of untreated BMS.
About 50-60% of BMS patients achieve significant symptom improvement (greater than 50% reduction) with appropriate pharmacologic and behavioral treatments. Complete symptom resolution occurs in 30-40% of treated patients within 12-18 months.
Long-term management requires sustained pharmacologic therapy. Most patients require continued medicine indefinitely to maintain symptom control. Medicine discontinuation frequently results in symptom recurrence within weeks to months.
Treatment-resistant BMS (approximately 20-30% of patients failing standard interventions) may warrant addition of multiple medicine classes, optimization of existing medicines, or factor of other option approaches (specialist consultation, experimental therapies).
Patient support groups and educational resources reduce psychological burden and provide coping strategy sharing among patients. BMS organizations provide evidence-based information and support community resources.
Summary and Clinical Recommendations
Burning mouth syndrome represents a chronic neuropathic orofacial pain condition affecting 0.7-4.6% of the general population. Peak incidence is in postmenopausal women. Diagnostic criteria require intraoral burning sensation more than 4 hours daily for 3+ months. The mouth looks clinically normal. There is absence of other option pathology.
Etiology appears multifactorial. It involves peripheral trigeminal nerve problem, central sensitization processes, and potentially salivary problem, psychological factors, and hormonal influences. Primary pathophysiologic processes remain incompletely understood. This contributes to variable treatment response.
Differential diagnosis must exclude oral candidiasis, lichen planus, xerostomia, trigeminal neuralgia, and other local/systemic pathology. Use careful history, clinical exam, and appropriate laboratory testing.
Management emphasizes cognitive-behavioral therapy, psychological support, and pharmacologic treatments. Tricyclic antidepressants (amitriptyline) and gabapentin show highest efficacy. They show 60-70% and 50-60% significant improvement rates respectively. SSRIs, benzodiazepines (short-term), and alpha-lipoic acid provide other option options for partial responders or patients with medicine contraindications.
Orofacial pain specialist referral should be considered when standard treatments prove ineffective or diagnostic uncertainty persists. Long-term sustained medicine therapy is typically required to maintain symptom control. Most patients require indefinite treatment to prevent recurrence.
Every patient's situation is unique—always consult your dentist before making treatment decisions.Related reading: Tooth Restoration Comparison and Your Guide to Dental Procedure Planning.
Conclusion
Learn more: Oral pain management, Menopause and oral health, or Finding pain specialists.
> Key Takeaway: Burning mouth syndrome is a chronic neuropathic pain condition affecting 0.7-4.6% of people (especially postmenopausal women), looks normal on examination, and responds best to medication combined with cognitive-behavioral therapy.